LYSA ongoing programs with decisional interim PET

O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France



3 phase III trials

- DLBCL
 - LNH 09-1B: aalPl = 0, 18 80y
 - **GAINED**: aaIPI = 1-3, 18 60y
- Hodgkin Lymphoma
 - AHL2011: advanced HL, 16 60y



PET Logistic/review

PETO, 2 and 4 are successively downloaded on IMAGYS web platform

Review by 2 nuclear medicine experts

•Therapeutic strategy depends on review result (2 same results needed to send conclusion (either local+expert, either 2 experts)

Results of review send by email to the investigator, CRA monitor, project manager, PET Coordinator and Local Nuclear physician.



LNH2009-1B

Randomized Phase III study evaluating the non inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non hodgkin's lymphoma CD 20+

> Sponsor: LYSARC Chairmen: S. Bologna & JN Bastie Statistical coordinator: M Fournier Project manager: F. Morand

LNH2009-1B: rationale


• Previous results:

- Before the rituximab era
 - ACVBP was superior to CHOP + RT in 18-60y pts (Reyes F, NEJM 2005)
 - 4 x CHOP21 + RT is not superior to CHOP21 in pts > 60y (Bonnet C, JCO 2007)
- Since the Rituximab availability:
 - MinT: 6 x R-CHOP21 > 6 x CHOP21 in 18-60y pts (Pfreundschuh M, Lancet Oncol 2008)
 - Ricover 60: 6-8 R-CHOP14 > 6-8 CHOP14 in pts > 60y (30% aaIPI=0) (Pfreundschuh M, Lancet Oncol 2008)
- 6 x R-CHOP21 is considered by GELA/LYSA as the standard treatment of patients with aaIPI = 0 aged from 18 to 80 years



DLBCL: 18-80 y, aalPI=0

LNH 2009-1B



LNH 2009-1B: inclusion criteria

- Patient with histologically proven CD20+
 - Diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008)
 - Follicular lymphoma grade 3B
- Age from **18 to 80 years**
- Patient not previously treated
- Ann Arbor Stage : I or II
- Normal level of LDH.
- ECOG performance status (PS) < 2.
- Age-adjusted international prognostic index (aaIPI) = 0
- Baseline PET (PET0) performed before any treatment, even in absence of known lesion (for stage I for which the lesion has been removed for diagnostic reason)
- Having previously signed a written informed consent

LNH 2009-1B: Assumptions

- Phase III trial stratified by age (≤60 vs >60 yrs) and presence or not of high tumor burden (>10 cm)
- Primary end point: **PFS**
- Assumptions : Non inferiority in term of PFS of the strategy driven by PET, compared to the treatment no monitored by early PET
 - Standard arm : 3-year PFS = 80%
 - 3y-PFS >70% in the experimental arm (HR = 1.6)
- Sample size: N = 420 patients recruited over 3 years with a minimum follow-up of 3 years (114 events)

LNH 2009-1B: PET / CT Imaging

• PET review

- Nancy: P. Olivier
- Toulouse: A. Julian
- UC Louvain: T. Vander Borght
- Decisional PET interpretation: 5PS criteria (1,2,3, vs 4,5)
- Additionnal prospective analysis:
 - $-\Delta$ SUVmax
 - Hypermetabolic Tumor volume / CT Tumor volume
 - Total lesion glycolysis

GAIN NEwly Diagnosed DLBCL GAINED

A RANDOMIZED PHASE III STUDY USING A PET-DRIVEN STRATEGY AND COMPARING GA101 VERSUS RITUXIMAB IN COMBINATION WITH A CHEMOTHERAPY DELIVERED EVERY 14 DAYS (ACVBP OR CHOP) IN DLBCL CD20+ LYMPHOMA UNTREATED PATIENTS FROM 18 TO 60 YEARS PRESENTING WITH 1 OR MORE ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI

> Sponsor: LYSARC Chairmen: R.O.Casasnovas & S. Le Gouill Statistical coordinator: J.P. Jais Project manager: Alexia Schwartzmann

GAINED: rationale


• Previous results:

- aalPl 2-3:
 - LNH07-3B: R-ACVBP14 or R-CHOP14 ± ASCT in a PET guided strategy: 75% 2y-PFS (*Casasnovas O, Blood 2011*)
 - **GOELAMS 075**: R-CHOP14 ± ASCT in a PET guided strategy : 75% 2y-PFS (*Milpied N, ASH 2010*)
- aalPl 1:
 - LNH03-2B: R-ACVBP14: 2y-PFS 89% (Recher C, Lancet 2011)
- **GA101** (Obinutuzumab) is a good candidate to improve disease control:
 - Phase II Rituximab relapsed/refractory DLBCL: 30% ORR, 15% RC/RCu (Morschhauser F, ASH 2011)
 - Combination with CHOP21 is feasable (*Radford J, ASH 2011*)

• Patients stratification:

- Interim PET on the basis of visual analysis allows safely to avoid ASCT in 30% of patients (*Casasnovas Blood 2011*)
- PET guided strategy using Δ SUVmax criteria may avoid ASCT in 80% of patients

LNH 2007-3B : PFS according to Δ SUVmax PET0-2 and PET0-4




Median FU = 26 months

🖸 Gela 🗿 Gelarc

Casasnovas et al, Blood 2011

LNH 2007-3B : OS according to Δ SUVmax PET0-2 and PET0-4




Median FU = 26 months

🖸 Gela 🗿 Gelarc

Casasnovas et al, Blood 2011

GAINED DLBCL, 18-60y, aaIPI = 1-3: Phase III – 2 arms





GAINED: Assumptions

- Phase III trial stratified on aaIPI (1 vs 2-3) and Chemotherapy
- Primary end point: EFS
- Assumptions
 - Improvement of the 2y-EFS of 8% in the GA101-Chemo14 arm (HR = 0.73)
 - Standard arm : 2y-EFS of 65%
 - Event: PET positivity according to ∆SUVmax criteria after 2 or 4 induction cycles, progression or relapse, modification of planned treatment out of progression or death of any cause
- Sample size: 670 patients (drop out = 10%) recruited over 3 years, with a minimum follow-up of 3 years



GAINED: PET / CT Imaging

- PET review
 - Créteil: E Itti, M Meignan
 - Dijon: A Berriolo-Riedinger, O Humbert
 - Nantes: F Bodéré, C Milin
- Decisional PET interpretation
 - PET2: Δ SUVmax PET0-2 < or >66%
 - PET4: ∆SUVmax PET0-4 < or >70%
 - But:
 - If SUVmax of PET0 < 10 and Δ SUVmax < cutoff value: 5PS
 - If Δ SUVmax > cutoff value and SUVmax interim PET >5: 5PS
- Additionnal prospective analysis:
 - Hypermetabolic Tumor volume / CT Tumor volume
 - Total lesion glycolysis




AHL 2011

Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma

> Sponsor: LYSARC Chairman: R.O.Casasnovas Statistical coordinator: J.P. Jais Project manager: Stephanie Picard



HD9 – 10-years FFTF by treatment arm




Engert A, JCO 2009; 27: 2548

BEACOPP vs ABVD

Stage IIB- IV BEACOPP [esc x 4 + Baseline x 2] vs ABVD x 6

Median FU = 41 months




Federico M, JCO ,2009

BEACOPP vs ABVD

Stage IIB- IV BEACOPP [esc x 4 + Baseline x 4] vs ABVD x 6/8

Median FU = 61 months


FFP



Viviani S, NEJM 2011; 365: 203

OS


HD15



	8×BEACOPP _{ercealated} (N=705)	6× BEACOPP _{ercosisted} (N=711)
Causes of death — no. (%)		
Total	53 (7·5)	33 (46)
Hodgkin lymphoma	13 (1.8)	11 (1.5)
Toxicity of study chemotherapy	15 (2·1)	6 (0.8)
Secondary neoplasia	13 (1.8)	5 (0.7)
Toxicity of salvage treatment	2 (0.3)	2 (0.3)
Other†	6 (0·9)	6 (0.8)
Unclear	4 (0.6)	3 (0·4)

Engert A et al , Lancet 2012

AHL 2011





AHL 2011: Assumptions

- Phase III trial stratified on Stage (IIB vs III/IV) and IPS
- Primary end point: PFS
- Assumptions: Non inferiority in term of PFS of the strategy driven by PET, compared to the treatment no monitored by early PET
 - Standard arm : 85% 5y-PFS
 - The 5y-PFS should be superior to 75% in the experimental arm (HR=1.77)
- Sample size: 810 patients recruited over 6 years, with a minimum follow-up of 1 year (97 events)



AHL 2011: INCLUSION CRITERIA

- Patient with a first diagnosis of classical Hodgkin lymphoma according to WHO criteria excluding nodular lymphocyte predominant subtype
- Age of 16 to 60 years
- No previous treatment for Hodgkin lymphoma
- Ann Arbor stages:
 - IIB with mediastinum/thorax > 0.33 or extra nodal localization
 - III
 - IV
- Baseline 18-FDG PET scan (PET0) performed before any treatment with at least one hypermetabolic lesion
- WHO performance status <3
- With a minimum life expectancy of 3 months
- Having previously signed a written informed consent
- The patient must be covered by a social security system



AHL 2011: PET / CT IMAGING

- PET review
 - Creteil: M.Meignan
 - Dijon: A. Berriolo Riedinger
 - St Cloud: V. Edeline
- Decisional PET interpretation: modified 5PS criteria (1,2,3, vs 4,5)
- Additionnal prospective analysis:
 - $-\Delta SUVmax$
 - Hypermetabolic Tumor volume / CT Tumor volume
 - Total lesion glycolysis

AHL2011: PET Review criteria

Local and review interpretations <u>had to follow the 5PS criteria</u> <u>modified as following</u>:

The 5-point scale:

- •1. No uptake.
- •2. Uptake < mediastinum.
- •3. Uptake > mediastinum but \leq liver.
- •4. Uptake moderately more than liver uptake, at any site.

A moderately uptake more than liver uptake is define as an uptake more or equal than 140% of SUV max liver (assessed on 3 slides on the liver middle region)


•5. Markedly increased uptake at any site or new sites of disease.

A markedly uptake more than liver uptake is define as an uptake more or equal than 200% of SUV max liver (assessed on 3 slides on the liver middle region)

- > **PET positive** is defined by scale level 4 and 5 (as described above)
- > **PET negative** is defined by scale level 1, 2 and 3.



AHL 2011



AHL 2011: PET review

October 3, 2012:

•28/260 (11%) PET2+

•6/190 (3%) PET4+



Conclusions

- In curable diseases (HL, DLBCL), in which long term therapeutic related events matter and have to be reduced, the good PET NPV may help to drive therapeutic strategy
- Early PET may identify good risk patients who could benefit of a reduced exposure:
 - To intensified chemotherapy regimen (BEACOPPesc)
 - To an extensive number of cycles of chemotherapy
 - To intensified high dose therapy consolidation (BEAM + ASCT)

Without impairing disease control

